Clinical trial
A Phase 3, Placebo Controlled, Double-Blind, Randomized, Clinical Study to Determine Efficacy, Safety, and Tolerability of Pulsed, Inhaled Nitric Oxide (iNO) Versus Placebo in Symptomatic Subjects With PAH (Part 1 and Part 2)
NCT02725372 is registered in ClinicalTrials.gov with Bellerophon Pulse Technologies as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Placebo Controlled, Double-Blind, Randomized, Clinical Study to Determine Efficacy, Safety, and Tolerability of Pulsed, Inhaled Nitric Oxide (iNO) Versus Placebo in Symptomatic Subjects With PAH (Part 1 and Part 2)
- Lead sponsor
- Bellerophon Pulse Technologies
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- April 30, 2016
- Completion date
- August 31, 2018
- Enrollment
- 207 (actual)
- Sites
- 109
Conditions
As the registry lists them; a condition with its own page is linked.